Chinese clinical research service provider Hangzhou Tigermed Consulting Co. has won approval from the Hong Kong stock exchange for its second listing, which could raise about $1 billion in what would be Asia’s largest health-care listing this year, according to people familiar with the matter.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
